Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dyspareunia (Female) Clear all
Completed Phase 2 Interventional Results available

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

NCT02449902
View directory record Official record
Conditions
Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions
Estradiol, placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA

NCT02784613
View directory record Official record
Conditions
Vulvovaginal Atrophy, Dyspareunia
Interventions
Ospemifene
Drug
Lead sponsor
Sue Goldstein
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 24, 2026, 4:03 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial

NCT07260825
View directory record Official record
Conditions
Vulvodynia, Dyspareunia, Lichen Sclerosus of Vulva
Interventions
Estradiol 0.01% Vag Cream, testosterone 0.1% and estradiol 0.01% vaginal cream
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Diazepam Vaginal Suppositories for High Tone Pelvic Floor Dysfunction.

NCT01233791
View directory record Official record
Conditions
Female Patients With High Tone Pelvic Floor Dysfunction
Interventions
Vaginal Diazepam Suppository, Placebo Suppository
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

NCT02150525
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I, Breast Cancer, Stage II, Breast Cancer, Stage III
Interventions
omega-3 fatty acid, placebo, Questionnaire administration
Dietary Supplement · Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors

NCT03372720
View directory record Official record
Conditions
Cervical Carcinoma, Dyspareunia, Endometrial Carcinoma, Ovarian Carcinoma, Vaginal Carcinoma, Vaginal Dryness, Vulvar Carcinoma
Interventions
Laser Therapy, Questionnaire Administration, Sham Intervention
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Fargo, North Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

NCT02778399
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, OBE2109
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
71
States / cities
Chandler, Arizona • Scottsdale, Arizona • Arcadia, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Acupuncture for the Treatment of Vulvodynia

NCT02197429
View directory record Official record
Conditions
Vulvodynia, Vulvar Vestibulitis, Pain, Dyspareunia, Female Sexual Dysfunction Due to Physical Condition
Interventions
Acupuncture
Other
Lead sponsor
Schlaeger, Judith M., CNM, LAc, PhD
Individual
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Fractional CO2 Laser Therapy for Survivors of Breast Malignancies

NCT03307044
View directory record Official record
Conditions
Breast Carcinoma, Cancer Survivor, Cervical Carcinoma, Dyspareunia, Vaginal Dryness
Interventions
Laser Therapy, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2023 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause

NCT03178825
View directory record Official record
Conditions
Vaginal Atrophy, Sexual Dysfunction, Dyspareunia, Vaginal Dryness, Chronic UTI
Interventions
Hybrid Fractional Laser
Device
Lead sponsor
Sciton
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Gatos, California • Pensacola, Florida • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 24, 2026, 4:03 PM EDT
Recruiting No phase listed Observational

Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

NCT00499317
View directory record Official record
Conditions
Chronic Prostatitis (CP), Chronic Pelvic Pain Syndrome (CPPS), Painful Bladder Syndrome (PBS), Benign Frequency Syndrome (BFS), Interstitial Cystitis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Completed No phase listed Observational Results available

Laser Therapy for Treatment of Urogenital Symptoms in Women

NCT03681678
View directory record Official record
Conditions
Genitourinary System; Disorder, Female, Burning Vagina, Dyspareunia, Irritation; Vagina, Menopause Related Conditions, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Tract Infections, Stress Urinary Incontinence
Interventions
fCO2 Laser Therapy Group
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Not listed Phase 3 Interventional

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

NCT00458458
View directory record Official record
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Randomized, Controlled Trial With Hybrid Fractional Laser

NCT03647189
View directory record Official record
Conditions
Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia
Interventions
Hybrid Fractional Laser
Device
Lead sponsor
Sciton
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Early Phase 1 Interventional

Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness

NCT02029053
View directory record Official record
Conditions
Menopausal and Perimenopausal Disorder, Unspecified, Atrophic Vaginitis
Interventions
Vaginal Lubrication Ring for Vaginal Dryness
Device
Lead sponsor
J3 Bioscience, Inc.
Industry
Eligibility
35 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03654274
View directory record Official record
Conditions
Endometriosis
Interventions
Relugolix, Estradiol/norethindrone acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
60
States / cities
Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treating Postmenopausal Dyspareunia Where it Hurts

NCT03240081
View directory record Official record
Conditions
Dyspareunia
Interventions
50mcg estradiol cream, 100mcg estradiol cream
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 24, 2026, 4:03 PM EDT
Terminated Phase 3 Interventional Results available

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain

NCT04372121
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
23
States / cities
Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

NCT02670785
View directory record Official record
Conditions
Vulvovaginal Atrophy, Menopause, Dyspareunia
Interventions
Estradiol Vaginal Capsule (EVC), Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Tucson, Arizona • San Diego, California • New London, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Sep 24, 2026, 4:03 PM EDT
Suspended Phase 1Phase 2 Interventional

Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.

NCT01122342
View directory record Official record
Conditions
Vaginitis, Dyspareunia, Breast Neoplasms
Interventions
Testosterone propionate
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Pawtucket, Rhode Island • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 12, 2010 · Synced Sep 24, 2026, 4:03 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Study of Participants Ages 21-65 Diagnosed With Dyspareunia and the Effects of Low Intensity Shockwave Treatment

NCT05806203
View directory record Official record
Conditions
Female Dyspareunia
Interventions
Low intensity shockwave treatment to pelvic floor region plus typical physical therapy, Sham shockwave treatment plus typical physical therapy
Device
Lead sponsor
SoftWave Tissue Regeneration Technologies
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 24, 2026, 4:03 PM EDT
Not listed Phase 4 Interventional

Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome

NCT01312259
View directory record Official record
Conditions
Painful Bladder Syndrome, Interstitial Cystitis, Pelvic Floor; Insufficiency, Bowel Dysfunction, Sexual Dysfunction, Pelvic Floor; Incompetency
Interventions
Changing the Interstim parameter of '' Frequency" in patients with Interstitial Cystitis
Other
Lead sponsor
Pelvic and Sexual Health Institute
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 24, 2026, 4:03 PM EDT
Recruiting Phase 2 Interventional

Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women

NCT06197568
View directory record Official record
Conditions
Vulvo Vaginal Atrophy (VVA)
Interventions
Lasofoxifene Tartrate
Drug
Lead sponsor
Azure Biotech Inc.
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Life-Stress Interview for Women With Chronic Urogenital Pain Conditions

NCT02286115
View directory record Official record
Conditions
Chronic Urogenital Pain
Interventions
Life-Stress Interview
Behavioral
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 24, 2026, 4:03 PM EDT